Subscribe to NRx Newsletter

Highlight Articles

Featured image
NRx Announces Publication of Initial Findings of BriLife® Vaccine-produced Antibodies Against Omicron Variant

RADNOR, Pa., Jan. 27, 2022 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company has received scientific evidence from the Israel Institute for Biological Research (IIBR) that the BriLife® vaccine may produce effective […]

Continue Reading
Featured image
NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge

A Southwestern hospital has reported safety data collected under the Federal Right to Try law indicating that 16 of 19 patients (84%) with COVID-19 respiratory failure treated with ZYESAMI® by […]

Continue Reading
3PLAccelerated RecoveryACTIV-3ACTIV-3bActive3bAcute Respiratory Distress SyndromeAcute Respiratory FailureAdaptive Platform Trial DesignAnthony S Fauci MDARDSAviptadilAvitpadilBARDABig Rock PartnersBioConnect Virtual ConferenceBiotechBipolar DepressionBNP ParibasBoosterBreakthrough Therapy DesignationBRilifeBRILife®BTDCAHCardinal HealthCH HealthChaim HurvitzCheddar NewsClinical TrialsClosing BellCOID-19Commercial ForumlationCompassionate CareCovidCovid-19COVID-19 SurvivalCritical COVID-19CromosCytokine IL-6Cytokine StormCytokinesData Safety Monitoring BoardDeltaDelta VariantDenk PharmaDisease preventionDisease prevention & Control SummitDr YoDr. Sami SaidDry-powder InhalerDSMBEAPEkaterine TikaradzeEmegency Use AuthorizationEmergency UseEmergency Use Authorizationerectile dysfunctionEUAEuropean QPExpanded AccessFast TrackFDAFDA EmeFDA Emergency Use AuthorizationFDA Module 3Federal Right to Try ActFox BusinessGeorgiaGeorgia Society of PhysiciansGeorgian Ministry of HealthGILDGileadGovernment of LuxembourgH.C. Wainwright & Co.HC WainwrightHC Wainwright Annual Global Investment ConferenceHigh Flow NasalHoustonHouston MethodistHouston Methodist JC Walkter Jr Transplant CenterI-Spyi24 NewsICUIIBRIL-6 CytokineInhaled AviptadilIQVIQVIAiSpyIsraelIsrael Institute of Biological ResearchIV ZYESAMI®J. Georges YoussefJ&JJihad Georges YoussefJihad Georges Youssef MDJihad Geroges YoussefJournal of Infectious Diseases and TreatmentlawsuitLuxembourgLuxembourg Ministry of the EconomyMannkindMDMNKDMolnupiravirNanoPassNASDAQNation of GeorgiaNational Institutes of HealthNDA ZyesamiNehpron PharmaceuticalsNephronNephron PharmaceuticalsNIAIDNIHNRXNRx BriLife COVID VaccineNRx Business UpdateNRx EarningsNRX-100NRX-100/101NRX-101NRXPOmicronOrphan Drug DesignationPeptidesPharmacovigilancePrivate PlacementProf Jonathan JavittProf Jonathan Javitt MD MPHPTSDQ2 EarningsQ3 Finaincial ResultsQP AuditorQP DeclarationQuantum Leap HealthcareRemdesivirRespiratory Distress RatioRespiratory FailureRichard G Lugar Center for Public HealthRichard Luger CenterRIght to TryRLF-100RLF-100_002RTTSami SaidSar-CoV-2Sars-CoV-2Sever COVID-19Suicidal DepressionTechnosphereTESICOUCIUkraineUS Food and Drug AdministrationUSFDAVaccineVaccine TrialVaccine TrialsVasoactive Intestinal PeptideVekluryVIPVirologyZYESAMIZYESAMI®ZYESAMI™ZYESAMI™ INDZysamiZYSAMI®ZYSAMI® (aviptadil)